Bedaquiline represents both a novel chemical class - diarylquinolines (DARQs) - as well as a novel M.tb-selective mechanism of action (direct inhibition of M.tb ATP synthase). In animal models, this next-generation diarylquinoline appears more efficacious and potent against TB than bedaquiline and its predecessor, TBAJ-587, with a lower predicted clinical dose than either of those compounds. Similar to TBAJ-587, TBAJ-876 possesses improved safety properties compared to bedaquiline. 

Phase 1

Trial Components

Solo Compounds